Results 311 to 320 of about 126,141 (353)

JAK Inhibitor in CALR-Mutant Myelofibrosis

New England Journal of Medicine, 2014
na
PASSAMONTI, FRANCESCO, Caramazza, D., Maffioli, M.   +2 more
openaire   +6 more sources

JAK inhibitors in dermatology

Indian Journal of Skin Allergy, 2023
The four Janus Kinase (JAK) proteins and seven signal transducer and activator of transcription (STAT) factors mediate the intracellular signaling pathway of cytokine receptors, which are described in the pathogenesis of many autoimmune, allergic, and inflammatory dermatoses.
S. K. Shahriar Ahmed, Abhishek De, Aarti Sarda, Kiran Godse, Sandipan Dhar   +4 more
openaire   +1 more source

Emerging drug profile: JAK inhibitors

Leukemia & Lymphoma
Dysregulated JAK/STAT hyperactivity is essential to the pathogenesis of myelofibrosis, and JAK inhibitors are the first-line treatment option for many patients. There are four FDA-approved JAK inhibitors for patients with myelofibrosis. Single-agent JAK inhibition can improve splenomegaly, symptom burden, cytopenias, and possibly survival in patients ...
Alexander, Coltoff, Andrew, Kuykendall
openaire   +2 more sources

[JAK Inhibitors in Rheumatology].

Deutsche medizinische Wochenschrift (1946), 2019
In Germany, baricitinib and tofacitinib have been approved for the treatment of at least moderately active rheumatoid arthritis after the failure of conventional disease modifying anti-rheumatic drugs in 2017, and tofacitinib also for psoriatic arthritis and ulcerative colitis. Both baricitinib and tofacitinib can be taken orally and reversibly inhibit
openaire   +2 more sources

Current and future status of JAK inhibitors

Lancet, The, 2021
Janet E Pope, Jason Gotlib, Claire N Harrison   +2 more
exaly  

JAK kinase inhibitors

Drug Discovery Today, 2004
Christopher Burns, Andrew Wilks, Stephen Su   +2 more
openaire   +1 more source

JAK Inhibitors

2021
openaire   +1 more source

The JAK/STAT signaling pathway: from bench to clinic

Signal Transduction and Targeted Therapy, 2021
Xiaoyi Hu, Xia Zhao, Wei Wang
exaly  

JAK-Inhibitor mit Potenzial

Gastro-News, 2022
openaire   +1 more source

The role of JAK/STAT signaling pathway and its inhibitors in diseases

International Immunopharmacology, 2020
Shuang Liu
exaly